Cargando…

Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials

Background Physiological age-related changes in the haemostatic and coagulation systems result in differing anticoagulant assay responses to standard anticoagulants. Therefore, we investigated the response of anticoagulant assays to dabigatran etexilate (DE) in children compared with adults. Object...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maas, Hugo, Gropper, Savion, Huang, Fenglei, Stangier, Joachim, Tartakovsky, Igor, Brueckmann, Martina, Halton, Jacqueline M. L., Mitchell, Lesley G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202931/ https://www.ncbi.nlm.nih.gov/pubmed/30112751 http://dx.doi.org/10.1055/s-0038-1668132

Ejemplares similares

Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials
por: Mitchell, Lesley G., et al.
Publicado: (2022)

Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2018)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design
por: Luciani, Matteo, et al.
Publicado: (2018)

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017)

Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
por: Brandão, Leonardo R., et al.
Publicado: (2022)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
por: Glund, Stephan, et al.
Publicado: (2016)

Anticoagulant Related Nephropathy Induced by Dabigatran
por: Sharfuddin, Nazia, et al.
Publicado: (2018)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
por: Kairov, Gaisa T., et al.
Publicado: (2018)

Delayed concentration effect models for dabigatran anticoagulation
por: Eaton, Michael P., et al.
Publicado: (2022)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects
por: Ring, Arne, et al.
Publicado: (2013)

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
por: Glund, Stephan, et al.
Publicado: (2016)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
por: Giannandrea, David, et al.
Publicado: (2019)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

A novel oral anticoagulant, dabigatran, in acute renal infarction
por: Altın, Cihan, et al.
Publicado: (2015)

Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis
por: Zhou, Ya, et al.
Publicado: (2021)

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
por: Chung, Hyewon, et al.
Publicado: (2023)

Paediatric Teaching: Core Paediatric Conditions
por: Southwood, Taunton
Publicado: (1996)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
por: Verdecchia, Paolo, et al.
Publicado: (2018)

Paediatric HERMES: European accreditation of training centres in paediatric respiratory medicine
por: Sutter, Sandy, et al.
Publicado: (2016)

Pædiatrics
por: Allen, F. M. B.
Publicado: (1933)

PAEDIATRICS
Publicado: (1982)

PAEDIATRICS
Publicado: (1974)

Pædiatrics
Publicado: (1930)

Pædiatrics
Publicado: (1934)

Pædiatrics
Publicado: (1934)

Pædiatrics
Publicado: (1933)

Pædiatrics
Publicado: (1935)

Pædiatrics
Publicado: (1935)

Pædiatrics
Publicado: (1932)

Pædiatrics
Publicado: (1945)

Pædiatrics
Publicado: (1938)

Cannot write session to /tmp/vufind_sessions/sess_htbmf58le3seo2lci01fu7m76r